Intermittent Eating on Glucose Homeostasis in Prediabetes
Effects of Intermittent Eating on Glucose Homeostasis in Prediabetes: A Randomized Clinical Trial
1 other identifier
interventional
87
1 country
1
Brief Summary
Prediabetes is a high-risk state for diabetes development, lifestyle modification is the cornerstone of diabetes prevention. Two novel types of intermittent fasting recently have received more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast day. This randomized controlled trial aimed to evaluate the effect of TRE and the 5:2 diet on glucose homeostasis and cardiometabolic risk factors in prediabetes over 6 months compared to usual health care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 28, 2023
CompletedFirst Posted
Study publicly available on registry
February 8, 2023
CompletedStudy Start
First participant enrolled
April 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedNovember 9, 2023
November 1, 2023
1.3 years
January 28, 2023
November 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in percent of time in range (glucose between 3.9-7.8mmol/L) over 6 months measured with continuous glucose monitoring.
Baseline to months 6
Secondary Outcomes (21)
Change in mean glucose levels
Baseline and months 6
Change in glycemic variability
Baseline and months 6
Change in percent of time below range
Baseline and months 6
Change in percent of time above range
Baseline and months 6
Change in resting metabolic rate
Baseline and months 6
- +16 more secondary outcomes
Study Arms (3)
Time-restricted eating
EXPERIMENTALParticipants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
the 5:2 diet
EXPERIMENTALParticipants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Control
NO INTERVENTIONParticipants in the control group will receive a general lifestyle counseling.
Interventions
Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Eligibility Criteria
You may qualify if:
- Men or women aged 18-75 years;
- Prediabetes;
- Body mass index (BMI)of 28.0 to 45.0 kg/m2;
You may not qualify if:
- History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis;
- Diagnosis of type 1 and type 2 diabetes;
- History of malignant tumors;
- Serious liver dysfunction or chronic kidney disease (AST or ALT \> 3 times the upper limit of normal, or eGFR\<30 ml/min/1.73 m2);
- History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months;
- History of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months;
- History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity;
- Being a smoker or having been a smoker in the 3 months prior to their screening visit;
- Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician;
- Currently participating in weight loss programs;
- Women who are pregnant or plan to become pregnant;
- Patients who cannot be followed for 24 months (due to a health situation or migration);
- Patients who are unwilling or unable to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Huijie Zhang, MD.PhD
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 28, 2023
First Posted
February 8, 2023
Study Start
April 11, 2023
Primary Completion
August 1, 2024
Study Completion
December 1, 2024
Last Updated
November 9, 2023
Record last verified: 2023-11